National Institute on Drug Abuse
Director's Report to the National Advisory Council on Drug Abuse
February, 1999
Meetings/Conferences
NIDA organized a Town Meeting in Des Moines, Iowa entitled "Understanding Drug Abuse and Addiction: Myths versus Reality" on October 14, 1998. NIDA Director Dr. Alan I. Leshner and NIDA researchers discussed ways that state policy makers, organizations, schools and communities can utilize the latest scientific research to assess state and local drug problems and tailor programs to meet these needs. Dr. Timothy Condon gave a presentation entitled "Focus on Methamphetamine," addressing a drug problem particular to the region.
NIDA hosted its Fifth Annual Constituent Conference on December 1-2, 1998 at the Lansdowne Conference Center in Lansdowne, Virginia. NIDA Director, Dr. Alan I. Leshner presented the 'NIDA Report Card' highlighting specific actions taken by the Institute in response to constituent group recommendations and needs.
NIDA sponsored a Drug Abuse Track at the Community Anti-Drug Coalitions of America Annual National Leadership Forum in Washington, D.C., November 18-21, 1998.
The National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Office of Medical Applications of Research (OMAR) sponsored a 3-day NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder in November, 1998. After hearing presentations by national and international medical research and health care experts in the fields and public testimony from interested organizations and individuals, an independent, non-Federal consensus panel chaired by Dr. David Kupfer, Thomas Detre Professor and Chair, Department of Psychiatry, University of Pittsburgh, weighed the scientific evidence and wrote a draft consensus statement. Among the findings the panel made were: 1) careful therapeutic use of stimulants is effective in treating the core symptoms of ADHD, 2) although increased risk of drug abuse and cigarette smoking is associated with childhood ADHD, existing studies come to conflicting conclusions as to whether exposure to psychostimulant medication increases or decreases the subsequent risk of abuse, and 3) while increased availability of stimulant medications may pose risks for society, there is little evidence that current levels of production have had a substantial effect on abuse. The full draft NIH Consensus Statement on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder is available by calling 1-888-NIH-CONSENSUS (1-888-644-2667) or by visiting the NIH Consensus Development Program Web site at http://consensus.nih.gov.
NIDA sponsored a Drug Abuse track at the annual conference of the New York State Alcoholism and Substance Abuse Programs Associations in Saratoga Springs, New York, on October 27, 1998. NIDA Director, Dr. Alan Leshner, was the keynote speaker at this event.
NIDA sponsored a mini-town meeting in conjunction with the University of Buffalo, in Buffalo, New York, on October 28, 1998.
On December 1, 1998 the Medications Development Division held a quarterly meeting with its participating Department of Veterans Affairs Medications Development Research Units (MDRUs). The meeting focused on changing certain administrative aspects of the MDRU program and transferring the VA's locus of administrative oversight from its Medical Research to its Cooperative Studies Program in order to promote management efficiencies.
On July 29, 1998, NIDA's Medications Development Division held a review of Alpha-2 Adrenergic Agonists: Feasibility of Inpatient v. Outpatient Efficacy Studies Directions. This meeting of internationally recognized leaders in the field concerning the use of alpha-2 agonists as treatments for opiate withdrawal was convened to review evidence and formulate optimal research strategies for evaluating relatively novel medications in this class as treatments for opiate withdrawal. Participant reviewers included G.E. Bigelow, Ph.D., Johns Hopkins University School of Medicine, C. Gorodetzky, M.D., Ph.D., Hoechst Marion Roussel, H. D. Kleber, M.D., Columbia University, T. R. Kosten, Yale University School of Medicine, L. McNicholas, M.D., Ph.D., University Pennsylvania School of Medicine, J. Myles, M.D., Avon Drug Problem Team, UK, S. A. Reines, M.D., Ph.D., Merck Research Laboratories, and J.A. Renner, Jr., M.D., Boston VA MDRU. Other Presenters were G. Gerra, M.D., Az. USL, Distretto "Parma Citta", Italy, M.S. Gold, M.D., University of Florida Brain Institute, D.R. Jasinski, M.D., Johns Hopkins University School of Medicine, and P.G. O'Connor, M.D., M.Ph., Y. Shaham. The focus was the feasibility of conducting inpatient versus outpatient studies.
NIDA's Medications Development Division held a Lofexidine Project Review: Ad Hoc Consultants Meeting on Future Directions on July 30, 1998, at the Hyatt Regency Hotel in Bethesda, MD. Lofexidine is an alpha-2 adrenergic agonist that has previously been shown in open studies and recently (1996-1998) in double-blind trials to have similar efficacy but significantly less hypotensive effects than clonidine in the treatment of opiate withdrawal. As there is no FDA approved non-opiate medication for opiate withdrawal in the U.S., MDD, NIDA has been exploring lofexidine to fill this gap. Clonidine is an approved medication in the U.S. for the treatment of hypertension, but it is not approved for the treatment of opiate withdrawal. Lofexidine (up to 2.4 mg/day) is approved for opiate withdrawal in the UK where over 45,000 doses have been administered to date. The meeting was convened to evaluate results of completed two site Phase I tolerability/preliminary efficacy trial (evaluating highest dose: 4.0 mg/day) conducted at the Philadelphia VA Medications Development Research Unit (MDRU) and at the Los Angeles (now Long Beach) VA MDRU to provide external peer review evaluation as to whether MDD, NIDA should move forward to an inpatient double-blind pivotal multi site Phase II/III trial. Results of this meeting: All 7 consultants indicated that MDD, NIDA should go forward with the proposed Phase II/III study.
On August 13-18, 1998, NIDA's Special Populations Office cosponsored "Diversity 2000" at the annual convention of the American Psychological Association in San Francisco, California. This program encourages minority community college students to develop leadership skills and pursue advanced degrees and research careers.
Dr. Alan I. Leshner, NIDA Director, presented the keynote address at the "Primary Care/Behavioral Healthcare Summit," held in St. Louis, Missouri, November 3-6, 1998.
Dr. Timothy Condon, Associate Director, NIDA and Director, Office of Science Policy and Communications (OSPC), attended the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, held October 28 - November 1, 1998 in Anaheim, California.
Dr. Timothy Condon, Dr. Andrea Baruchin, and Dr. Cindy Minor of OSPC attended the Society for Neuroscience Annual Meeting in Los Angeles, California, November 9 - 13, 1998. Dr. Baruchin presented at the 'Survival Skills Workshop on Job Hunting' and Dr. Baruchin and Dr. Minor participated in a trans-NIH research training session.
Dr. Timothy Condon traveled to Omaha, Nebraska to represent NIDA at the Second Meeting of the Methamphetamine Interagency Task Force Federal Advisory Committee held October 5-6, 1998.
Dr. Timothy Condon presented the keynote address "Drugs and The Brain: Can Science Replace Ideology?" at the meeting of Join Together National Leadership Fellows held in Hilton Head, South Carolina on September 17, 1998.
Dr. Andrea Baruchin, OSPC Science Policy Branch Chief, attended the "Community and Science: Models for Success" meeting, a bioethics workshop held in Tuskegee, Alabama on November 19-20, 1998.
Dr. Cindy Miner conducted a grant writing workshop at the American Academy of Child and Adolescent Psychiatry held in Anaheim, California on October 28, 1998.
Drs. Cindy Miner and Cathrine Sasek, OSPC, gave a presentation entitled "The Effects of Drugs on the Brain" on November 20, 1998 at the CADCA National Leadership Forum in Washington D.C., November 18-21, 1998.
On September 23, 1998, Dr. Timothy Condon, Associate Director, NIDA, and Beverly Jackson, Chief, Public Information and Liaison Branch, OSPC, attended the NIH meeting hosted by Dr. Varmus, "Enhancing Public Participation in NIH Activities."
On November 6, 1998, Beverly Jackson participated in the planning meeting for the 1999 Recovery Month activities, organized by the Center for Substance Abuse Treatment.
On November 12, 1998, Dr. Timothy Condon and Beverly Jackson participated in a day-long conference on outreach to the entertainment industry held in Los Angeles, CA.
On November 19-20, 1998, Drs. Alan Leshner and Lula Beatty chaired the Addictions Panel at the NIH sponsored "Community and Science: Models for Success" conference held at Tuskegee University in Tuskegee, Alabama. This conference was a follow-up activity in response to the President's apology for the PHS syphilis study conducted in Tuskegee. Addictions Panel members included Dr. Leshner and past/current NIDA Council members, Drs. Lawrence Brown, Kathy Sanders-Phillips, and Andrea Barthwell.
On September 18-20, 1998, as a part of the semiannual meeting of governance boards and committees, Dr. Lula Beatty participated in the American Psychological Association's Committee on Women's meeting.
On October 1, 1998, Dr. Lula Beatty attended the Advisory Board meeting of the Office of Research on Minority Health.
On October 15, 1998, Dr. Lula Beatty attended a conference on Racial Trends sponsored by the National Academy of Science.
On September 16-19, 1998, Ana Anders, Senior Advisor on Special Populations, Special Populations Office, chaired a workshop entitled "Impact of Welfare Reform on Substance Abuse: Requirements on Latino Families and Community" at the NIDA cosponsored Latino Behavioral Health Institute Conference in Los Angeles, California. Dr. Alan Leshner, Director, NIDA, was a keynote speaker at this conference.
On October 8, 1998, Ana Anders participated in a daylong retreat with Hispanic colleagues from other NIH institutes in order to review the charter on responsibilities of the Hispanic Task Force.
On October 13, 1998, Ana Anders represented NIDA on the MADD diversity Committee at a planning meeting for the upcoming National Diversity Forum.
On October 14, 1998, Ana Anders represented NIDA at the NIH Hispanic Task Force meeting with Dr. Ruth Kirchstein, Deputy Director, NIH. They met to review and recommend actions for the Hispanic Agenda at NIH.
As a representative of NIDA, Ana Anders has attended ongoing meetings with multiple federal agencies hosted by ONDCP. They have met to finalize the U.S./Mexico Demand Reduction portion of the Binational Drug Strategy document and to design a Web page to allow better avenues of communication between the two countries.
On December 8, 1998, Pamela Goodlow, Special Populations Office, presented an overview of NIDA's minority supplements program to NIDA staff. Topics covered included history of the program, policy and review procedures for minority supplements, and eligibility concerns.
Dr. Frank Vocci, Director, MDD, and Dr. Walter Ling briefed the California Research Advisory Panel on the development of buprenorphine and buprenorphine/naloxone on September 23, 1998.
Dr. Frank Vocci and Mr. Joel Egertson, MDD, briefed the Board of Directors of the American Methadone Treatment Association at their annual meeting held in New York City on Sept 28, 1998.
Drs. Tim Condon and Frank Vocci, and Ms. Mary Mayhew briefed Mr. Mark Wheat on the development of medications for the treatment of addictive disorders on October 6, 1998.
Barbara H. Herman, Ph.D., MDD, chaired a meeting of the P50 Medications Centers Grantees entitled Interim Center Grant Update on Medications for Cocaine, Opiate, and Nicotine Abuse/Addiction on March 4-5, 1998, in Washington, D.C. Principal Investigators (PIs) and Co-Investigators from the five P50 medications center grants were asked to present interim update on medications for addictive disorders from each center, and to encourage interaction and scientific exchange among the center participants. PIs of these centers include:
J. Grabowski, Ph.D., University of Texas (Houston); Dorothy Hatsukami, Ph.D., University of Minnesota; Herbert D. Kleber, M.D., Columbia University; Thomas R. Kosten, M.D., Yale University and VA Connecticut Health Care System; Walter Ling, M.D., UCLA and Los Angeles (now Long Beach) VAMC. In addition to presentations by the PIs there were 15 presentations by co-investigators from these sites.
Stephen R. Zukin, M.D., Director, Division of Clinical and Services Research (DCSR), was a speaker at the 10th Annual St. Thomas Hospital Conference on Addictions in Akron, Ohio on November 4, 1998. Dr. Zukin's speech was entitled Progress in Treatment: From Research to Practice.
Jack Blaine, M.D., Chief of the Treatment Research Branch, DCSR, was the keynote speaker at the Community Forum on November 16, 1998 sponsored by the San Francisco Treatment Research Center on "Bridging the Gap Between Drug Abuse Treatment and Research."
Jack Blaine, M.D., participated in a symposium on Contingency Management Approaches to the Treatment of Drug Abuse at the 9th Annual Meeting of The American Academy of Addiction Psychiatry, December 3-6, 1998 in Amelia Island, FL. He also participated in the Biopsychosocial Research Committee and the Multi-Treatment Committee, and participated in a "lunch with experts" discussion on developing a substance abuse research career.
Drs. Harold Gordon and Steven Grant, ECNB, DCSR, attended the annual meeting of the Society for Neuroscience in Los Angeles, November 1998.
Arthur MacNeill Horton, Jr., Ed.D., ECNB, DCSR, represented NIDA at the HIV/CNS Tissue Network, Steering Committee Meeting, held at the Natcher Conference Center on December 1-2, 1998.
Dr. Harold Gordon, ECNB, DCSR, chaired and co-organized with Jonathan Pollock, Ph.D. as part of the Genetics Workgroup, a NIDA-sponsored Satellite Symposium entitled "Prospects for the Molecular Genetics of Drug Abuse" held in conjunction with the annual meeting of the American Society of Human Genetics in Denver, CO on October 27, 1998.
Dr. William Cartwright made a presentation on pharmacoeconomics at the 38th Meeting of New Clinic Drug Evaluation Unit on June 12, 1998, entitled "Which Drug Shall Die?"
Dr. Bennett Fletcher spoke on improving drug abuse treatment and NIDA's treatment and health services research agenda at the North Carolina Council of Community Programs held in Pinehurst, North Carolina on December 7, 1998.
Richard H. Needle, Ph.D., M.P.H., Chief, CRB, DEPR, was an invited keynote speaker at the "Opening Event" of the Center for Drug Use and HIV Research, held September 28, 1998 at National Development and Research Institutes (NDRI), Inc., in New York City. Dr. Needle's presentation addressed the origins, evolution, and current status of NIDA's HIV prevention research and intervention programs. The event represented the Center's formal establishment at NDRI, made possible by a NIDA Core Center grant award to the Center's Director, Sherry Deren, Ph.D.
Dr. Elizabeth Robertson presented a workshop titled "Methamphetamines and Other Drugs in Rural America" in conjunction with Drug Enforcement Agency (DEA) staff at the Community Anti-Drug Coalitions of America (CADCA) National Leadership Forum on November 20, 1998 in Washington, D.C.
Richard H. Needle, Ph.D., M.P.H., Chief, CRB, DEPR, participated as a Special Discussant in a panel on "Needle Exchange Programs: Roles in HIV Prevention and as Conduits to Substance Abuse Treatment," at the 126th Annual Meeting of the American Public Health Association, on November 16, in Washington, D.C. Dr. Needle's presentation was entitled "The Importance of Research on Sterile Syringe and Needle Exchange Programs."
Drs. Elizabeth Robertson and Kathy Etz, DEPR, participated in a Performance Enhancement Protocol System (PEPS) planning group meeting convened by CSAP on October 5-6, 1998. The planning group reviewed the status of current PEPS documents and discussed future guidelines, documents and dissemination and evaluation plans.
Richard H. Needle, Ph.D., M.P.H., Chief, CRB, DEPR, served as discussant for a panel session at the Annual Meeting of the American Anthropological Association, held in Philadelphia in December 1998. Dr. Needle's presentation described the history and importance of ethnography in the conduct of community-based HIV and drug abuse prevention research.
Peter Hartsock, Dr.P.H., CRB, DEPR, represented NIDA at Yale University's historical research conference, "100 Years of Heroin," held September 18-20, 1998 in New Haven, CT. This year marks the 100th anniversary of the development of "medicinal" heroin by the Bayer Corporation. ale University's Dr. David Musto, a widely renowned drug abuse historian and NIDA grantee, chaired the conference. Participants included scholars as well as former and current government officials who have made significant contributions to the development of drug abuse intervention strategies, many of which are in use today. Senator Daniel Patrick
Moynihan of New York was the Conference's keynote speaker. Dr. Hartsock gave a presentation on historical research opportunities at NIDA.
Arnold Mills, CRB, DEPR, represented NIDA at the Native American Symposium held in Tucson, Arizona, October 21 - 22, 1998. The Symposium focused on issues related to the conduct of research in Native American communities, including Institutional Review Board (IRB) concerns, the identification and development of effective strategies for involving Native Americans in drug abuse research, and funding mechanisms for collaborative research on drug abuse and its consequences in Native American communities.
Jacques Normand, Ph.D., CRB, DEPR, gave a briefing on findings from the NIDA-sponsored NRC/IOM report, "Under the Influence? Drugs and the American Workforce," at the meeting of the Committee on Data and Research for Policy on Illegal Drugs, held by the National Research Council of the National Academy of Sciences on November 20, 1998 in Irvine, CA.
Jacques Normand, Ph.D., of CRB, DEPR, served as discussant for a panel session on "The Effectiveness of HIV Interventions for Out-of-Treatment Drug Users: Main Findings of the 1993-1997 NIDA Cohort," held at the 126th Annual Meeting of the American Public Health Association, on November 17, 1998 in Washington, D.C.
Dr. Kathy Etz, DEPR, participated in an ONDCP working group, Prevention Principles and Policies, that developed logic models and glide paths and determined data issues and resources to assist ONDCP in refining the Performance Measure of Effectiveness System. After multiple meetings, the working group made their recommendations to the steering group in October 1998.
Dr. Kathy Etz, DEPR, participated as NIDA's representative in the Join Together Information Exchange, October 15, 1998. The exchange provides an opportunity for those working in the public and private sectors to share information on preventing and reducing substance abuse.
On November 18, 1998, Dr. Kathy Etz, DEPR, represented NIDA at CADCA's National Leadership Forum, participating in workshops on Prevention Principles when Dealing with Youth and Strategies for Environmental Change.
Dr. Kathy Etz, DEPR, represented NIDA at the American Society of Criminology's annual meeting held November 11-14, 1998 in Washington, D.C. The meeting provided a unique opportunity to meet with criminologists who focus on interventions and outcomes for substance abusers.
On November 5-6, 1998, Drs. Kathy Etz and Elizabeth Robinson, DEPR, represented NIDA at NIH's conference on Preventive Intervention Research at the Crossroads: Contributions and Opportunities from the Behavioral and Social Sciences. The conference showcased examples of NIH supported prevention intervention research, highlighted contributions of behavioral and social science to prevention research and provided recommendations for opportunities in prevention research.
Dr. Rita Liu, Receipt and Referral Officer for NIDA, conducted a training session with staff from the Division of Basic Research and other NIH components at the Society for Neuroscience annual meeting in Los Angeles, November 7, 1998. The session entitled Grantsmanship for New Investigators Workshop, was sponsored by the Society and organized by NIMH.
Mr. Richard Harrison, Chief, Contracts Review Branch, represented the NIH at the National Congress of American Indians Annual Conference in Myrtle Beach, SC in October 1998. He also participated in an NIH panel to discuss employment, training, and internship opportunities at NIH during the American Indian Science & Engineering Society Annual Conference in Denver, November 18 - 21, 1998.
Mr. Eric Zatman, Contracts Review Branch, has represented NIDA at the NIH Worksite Health Promotion Action Committee, which is charged with creating and implementing health enhancement programs and establishing NIH as a national leader in worksite health promotion. In November, he was made Chair of the Physical Fitness Subcommittee.
Dr. Teresa Levitin evaluated scientific projects submitted for the fifty-eighth annual Science Service competition for high school students. This competition, which was formerly sponsored by Westinghouse and is now sponsored by Intel, took place in December 1998 at the Science Service offices in Washington, DC.
Mr. Richard Harrison represented NIH on the Interagency American Indian/Alaska Native Committee to coordinate activities related to the American Indian/Alaska Native Heritage Month celebrations in November 1998. In December 1998, he met with the Federal Interagency Committee on Alcohol and Substance Abuse in Indian Country, chaired by the Assistant Secretary for Indian Affairs, Department of the Interior.
Dr. Kenzie Preston, IRP, presented "Combined Behavioral and Pharmacological Treatment of Opioid Dependence" at the annual scientific meeting of the International Council of Alcoholism and Addiction in St. Julians, Malta, in September, 1998.
Dr. Roy Pickens, IRP, presented papers on "Genetics of Drug Abuse: Effects of Parental Substance Abuse on Methadone Maintenance Outcome" and "Cost Effectiveness of Treatment for Pregnant Drug Dependent Women" at the annual scientific meeting of the International Council of Alcoholism and Addiction in St. Julians, Malta, in September, 1998.
Nine members of the Intramural Research Program's Chemistry and Drug Metabolism Branch presented their research findings at the Society of Forensic Toxicology/The International Association of Forensic Toxicologists meeting in Albuquerque, NM in October 1998.
Dr. David A. Gorelick of the Treatment Branch of the intramural program presented Psychiatry Grand Rounds on "Pharmacological Treatment of Cocaine Addiction" at the West Los Angeles VA Medical Center, Los Angeles, CA on August 20, 1998.
Drs. Masato Asanuma and Jean Lud Cadet, IRP, presented "Attenuation of Methamphetamine- induced Increase in Striatal NF-KB Activity in Superoxide Dismutase Transgenic Mice" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Dr. Jean Lud Cadet, IRP, presented "Dopamine-induced Apoptosis is Abrogated in Immortalized Neural Cells Overexpressing Bcl-2" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Drs. Teruo Hayashi, Hiroshi Hirata, Masato Asanuma, Li-I Tsao, Tsung-Ping Su, and Jean Lud Cadet, IRP, presented "Induction of p53 mRNA by Methamphetamine (METH) is Blocked by [D-ALA2, D-LEU5]Enkephalin (DADLE) Via Nonopioid Action: Potential Mechanism Underlying the Protective Effect of DADLE against METH-induced Neurotoxicity" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Mike McCoy and Dr. Jean Lud Cadet, IRP, presented "Differential Display Evidence for Increased Vimentin Expression during Methamphetamine-induced Apoptosis in Vitro" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Dr. Roman Stefanski, Bruce Ladenheim, Dr. Jean Lud Cadet and Dr. Steven Goldberg, IRP, presented "Neuroadaptations to Methamphetamine Self-administration in Rats: Contingent vs. Noncontingent Infusions of Drug" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Dr. Subramanian Jayanthi, Bruce Ladenhiem, Dr. Anne Andrews, and Dr. Jean Lud Cadet, IRP, presented "Overexpression of Human Copper/Zinc-Superoxide Dismutase in Transgenic Mice Attenuates Oxidative Stress Caused by Methylenedioxy-methamphetamine (MDMA, Ecstasy)" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Drs. Li-I Tsao, C. Chiueh, Jean Lud Cadet and Tsung-Ping Su presented "[D-ALA2,D-LEU5] Enkephalin (DADLE) is a Free Radical Scavenger in Vitro: Implications for DADLE's Protective Action against Methamphetamine (METH)-induced Neurotoxicity" at the Society for Neuroscience's annual meeting held in Los Angeles, CA, November 7-12, 1998.
Dr. David A. Gorelick, IRP, presented an invited lecture on "The Neurobiology of Addiction and its Implications for Medical Practice," at the American Osteopathic Academy of Addiction Medicine annual meeting, New Orleans, LA on October 6, 1998.
Dr. D. Bruce Vaupel, IRP, presented "5-[123I]iodo-A-955380: A Promising Radiotracer for SPECT Imaging of Nicotinic Acetylcholine Receptors (nARChRs)" at The NIH Research Festival held in Bethesda, MD, October 7-9, 1998.
Dr. Katherine Bonson, IRP, presented "Validation of an Analytic Method of Calculating Cerebral Glucose Metabolism Using PET" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Daniella Gundisch, IRP, presented "Evaluation of High Affinity [3H] Epibatdine Binding in Rat Brain" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Ms. Geraldine Hill, IRP, presented "Acute and Chronic Effects of Methamphetamine on Cerebral Glucose Metabolism" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Alane S. Kimes, IRP, presented "Ex Vivo and In Vitro Autoradiographic Analysis of Nicotinic Acetylcholine Receptors Using 5-[125I]iodo-A-85380" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Andrei Koren, IRP, presented "Synthesis and Evaluation of Halogenated Analogs of A-85380 as Ligands for Nicotinic Acetylcholine Receptors" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. John Matochik of the intramural program presented "Age-Related Decline in Striatal Volume in Monkeys as Measured by MRI" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Alexey Muhkin, IRP, presented "5-iodo-A85380-a Novel Highly Selective Ligand of a4b2 Subtype of Nicotinic Acetylcholine Receptors" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Monique Ernst, IRP, presented "Nicotine and Cerebral Blood Flow During a Working Memory Task" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. D. Bruce Vaupel, IRP, presented "5-[125I]iodo-A-85380: Evaluation as a Radiotracer for the In Vivo Imaging of Nicotinic Acetylcholine Receptors in the Mouse" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Svetlana Chefer, IRP, presented "In Vivo Imaging of Brain Nicotinic Acetylcholine Receptors with 5-[123]iodo-A-85380 Using Single Photon Emission Computed Tomography" at the 27th Annual Meeting of the Society for Neuroscience, Los Angeles, CA, November 7-12, 1998.
Dr. Aviv Weinstein, IRP, presented "Activation of Craving in Cocaine Abusers While Performing the Continuous Performance Task-Can Cocaine Abusers Divide their Attention?" at the 37th Annual American College of Neuropsychopharmacology Meeting, Las Croabas, Puerto Rico, December 14-18, 1998.
Drs. Edythe D. London and Monique Ernst, IRP, co-chaired a panel, entitled "Cerebral Responses to Nicotine: From the Perspectives of Neuroimaging and Receptor Dynamics" and Dr. London participated in a study group entitled "Measurement of Alcohol and Other Drug Reactivity and Craving in the Animal and Human Laboratory: Issues of Design, Ethics, and Interpretation" at the 37th Annual American College of Neuropsychopharmacology Meeting, Las Croabas, Puerto Rico, December 14-18, 1998.
For additional information about NIDA send e-mail to Information@nida.nih.gov
[NIDA Home Page][Office
of the Director][Report Index][Previous
Report Section] [Next Report Section]
|
